Pharmacokinetics and Safety of ALA in Acne Vulgaris

NCT ID: NCT04044898

Last Updated: 2022-03-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-01-12
• Study Completion Date: 2021-12-06

Brief Summary

This study will evaluate the pharmacokinetics and safety of ALA in patients with moderate and severe acne vulgaris after single dose in different dosages.

Conditions

Acne Vulgaris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Low dose

Group Type: EXPERIMENTAL

ALA 5%

Intervention Type: DRUG

prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose

High dose

Group Type: EXPERIMENTAL

ALA 10%

Intervention Type: DRUG

prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose

Interventions

ALA 5%

prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose

Intervention Type: DRUG

ALA 10%

prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male and female subjects between 18 and 45 years of age (all subjects are male in pilot study);

2. Diagnosis of moderate to severe facial acne vulgaris by the clinician according to the Pillsbury International Improvement Classification III-IV criteria;

3. Body weight≥50 kg, body mass index (BMI) ≥19 and ≤28 kg/m2；

4. Subjects (including male subjects) voluntarily adopt effective physical contraception from 14 days prior to the use of the study drug to 1 month after the end of the study, and have no fertility or donation of sperm/egg plan;

5. Subjects voluntarily sign informed consent forms after being informed of the study procedures，requirements and possible adverse reactions of the study drug.

Exclusion Criteria

1. Suffer from allergic diseases ，suspect or known to have porphyrin disease or known to be allergic to test medication and/or porphyrin， or allergic persons (such as allergies to two or more drugs, food or pollen);

2. Allergies to visible light

3. Secondary acne patients, such as acne caused by occupational acne and corticosteroids.

4. Suffering from malignant tumors and suffering from diseases such as heart, endocrine, blood, liver, immunity, metabolism, urinary system, lungs, nervous system, rheumatism/joint, mental, kidney, etc led the researchers to believe that the subject is not suitable for participating in this study

5. Have been treated with systemic Vitamin A acid drugs therapy within 2 months before the study and/or antibiotics or hormonal drugs within 4 weeks before the study

6. Used local topical vitamin A acid drugs within the 4 weeks before the study or patients with topical antibiotics, glucocorticoid and other topical treatment of acne drugs within the 2 weeks before the study

7. Vaccination within 4 weeks prior to the use of the study drug;

8. Severe external injuries were suffered within the first 3 months (90 days) prior to the use of the study drug, or Patients who have undergone surgical treatment may significantly affect the process of studying drugs in vivo or safety assessment;

9. Taked clinical trial drugs within 3 months (90 days) prior to the use of the study drug, or be participating in or plan to participate in other clinical trials during the study period.

10. Drinking alcohol regularly within 3 months (90 days) prior to the use of the study drug (≥3 times a week, and the average drink is equivalent to 50° white wine ≥200 mL) or can not quit drinking during the study, or alcohol breath test positive

11. Smoking cigarettes (more than 10 cigarettes or equivalent of tobacco per day) within 3 months (90 days) prior to the use of the study drug or those who cannot quit smoking during the study;

12. Blood loss/blood donation more than 300 mL (except for female physiological blood loss), blood transfusion or blood product use within 3 months (90 days) prior to the use of the study drug, or plan to be blood donors during the study period or 1 month after the end of the study l (30 days) )

13. Consumed excessively daily tea, coffee or caffeinated beverages (up to 8 cups per day, 200 mL per cup) within 1 month (30 days) prior to the use of the study drug;

14. Drinks or food intake excessive of alcohol or caffeine (coffee, tea, cola, chocolate, etc.) within 48 hours prior to the use of the study drug ;

15. Have a history of drug abuse or positive drug abuse screening;

16. Hepatitis B surface antigen or hepatitis C virus antibody or treponema pallidum antibody positive or HIV Screening positive;

17. Physical examination (except acne), Vital Signs, laboratory examination (blood routine, urine routine, liver function, renal function, fasting blood glucose, blood lipids, etc).and 12 lead ECG results were judged to be abnormal and clinically significant by clinicians

18. Pregnant or lactating female; blood or urine pregnancy test positive

19. Have a history of blood or Needles fainting, or difficulty in collecting blood

20. Unable to complete the study for other reasons or Researchers believe that those who should not be included;

21. Researchers and their relatives including spouses and children will be not allowed to participate in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Huashan Hospital

Shanghai, Shanghai Municipality, China

Countries

China

Other Identifiers

F0014-ALA-201811

Identifier Type: -

Identifier Source: org_study_id